Tag Archive: biotech

May 27 2011

Bridging the Valley of Death: Bringing New Drugs from the Bench to the Clinic

Bridge

To bring a new medicine to the stage of clinical trial testing requires on the order of $500,000 to one million dollars and then seven to ten years of clinical trials and around $800 million dollars before getting to market.  However, it is doable, and one can point to successful biotechs such as Genentech, Amgen, …

Continue reading »

May 11 2011

Conference Recap – BayBio 2011

The BayBio Annual Conference 2011 was held on 20-21 April 2011 in Burlingame, CA.  The event was attended by more than 1,000 San Francisco Bay Area biotech and life sciences professionals from over 400 companies. This year’s conference focused on funding trends and emerging markets in the life sciences industry.  In keeping with BayBio’s spirit …

Continue reading »

Feb 28 2011

Recap of the 20th CED Biotech/Life Sciences Conference

The 20th Annual Council for Entrepreneurial Development (CED) Biotech/Life Science Conference was held on 21-22 February 2011 in Raleigh, North Carolina.

Feb 15 2011

Early Oncology Partnering Forum

From 21-22 February 2011, Cato Research will be attending the Early Oncology Partnering Forum held in San Francisco, CA.  This conference facilitates and encourages discussion and collaborations between companies that are developing innovative products with more established companies as partners. The conference will begin with a Partnering Perspective Presentation.  Representatives from Amgen, Eli Lilly, and …

Continue reading »

Feb 09 2011

CRO Industry Trends

The past few years have challenged Clinical Research Organizations (CROs) to adjust their business models to meet the changing needs of pharmaceutical and biotech companies. Most CROs saw disappointing 2009 earnings, especially those focused on early stage and nonclinical research, says Scrip Clinical Research, but many mid-sized CROs saw growth in 2010. Whether CROs will be able to sustain growth in 2011 remains unclear. What we do know is that the most successful ones will be those that embrace the three major industry trends – globalization, an increased use of preferred provider relationships, and a greater willingness to invest in new technology.

Dec 07 2010

Biotech Financing: Those That Adapt to Change Will Survive

In the October issue of Biotechnology Focus, Cato Research’s very own Chief Financial Officer and Principal of Cato BioVentures, Daniel Pharand, discusses the recent shift and latest trends in financing within the biotechnology industry.  “There have been a number of trends in the biotech funding world since its last bubble and bust in the early …

Continue reading »

Oct 26 2010

2010 Mid-Atlantic Bio Conference

Image via Wikipedia The 2010 Mid-Atlantic Bio conference will be held in Bethesda, MD from Wednesday, 27 October to Friday, 29 October.  Mid-Atlantic Bio is now in its sixth year and has become one of the country’s premier bioscience and investor conferences. The Mid-Atlantic Bio conference program combines networking events and education sessions to offer …

Continue reading »

Oct 26 2010

Vendor Selection – All that Glitters is Not Gold

One of the most important, and difficult, decisions a company has to make is selecting the right contract research organization (CRO) for outsourcing its nonclinical, manufacturing, clinical and regulatory activities.  Several variables determine what makes a good outsourcing partner – size compatibility between CRO and sponsor, the cost, and the experience level of the CRO …

Continue reading »

Jul 12 2010

Give Your Scientists an Edge – Partner with a CRO!

Image via Wikipedia In the fast paced R&D world, every biotech is looking for an edge to keep them ahead of their competitors and to help them achieve their goal of either getting a drug to human clinical trials or to a stage that attracts a big pharma partner.  In my 10 years of experience …

Continue reading »

Jun 18 2010

DIA 2010 – Week in Review

The DIA 2010 Annual Meeting was a great success and Washington, DC was a great location.  In addition to the thousands of industry attendees, the location made it possible for this year’s meeting to include FDA representatives from all areas of the Agency. As previously mentioned, Will Lee and I attended the meeting.  For those …

Continue reading »

Older posts «

» Newer posts